Jounce Therapeutics Inc. (NASDAQ:JNCE) traded with a subtraction of -$0.02 to close at $1.10 on Friday, a downside of -1.79 percent. An average of 10,524,739 shares of common stock have been traded in the last five days. There was a gain of $0.3019 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 3,482,055 shares traded, while the 50-day average volume stands at 1,650,310.
JNCE stock has increased by 45.47% in the last month. The company shares reached their 1-month lowest point of $0.5773 on 12/13/22. With the stock rallying to its 52-week high on 02/09/22, shares of the company touched a low of $0.58 and a high of $8.80 in 52 weeks. It has reached a new high 2 times so far this year and lost -86.59% or -$7.2300 in price. In spite of this, the price is down -87.50% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
JNCE stock investors should be aware that Jounce Therapeutics Inc. (JNCE) stock had its last reported insider trading activity 354 days ago on Jan 10. In this transaction, the insider spent $54,676. Chief Business Officer, Cole Hugh M, disposed of 6,205 shares at a price of $6.65 on Jan 10. The insider now owns more than $41,263 worth of shares. Prior to that, CEO and President MURRAY RICHARD /CA/ went on to Sale 23,924 shares at $6.65 each on Jan 10. An amount of $159,095 was transacted.
Jounce Therapeutics Inc. (JNCE) stock’s beta is 1.02. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.45.
The quick ratio of Jounce Therapeutics Inc. for the three months ended September 29 was 6.40, and the current ratio was 6.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $117.96 million compared to revenue of $26.91 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Jounce Therapeutics Inc.’s return on assets was -64.90%.
For the three-month period that ended September 29, Jounce Therapeutics Inc. had $51.5 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$31.0 million in the quarter, while revenues of -$33.51 million were grew 2.94%. The analyst consensus anticipated Jounce Therapeutics Inc.’s latest quarter earnings to come in at -$0.64 per share, but it turned out to be -$0.6, a 6.30% surprise. For the quarter, EBITDA amounted to -$30.69 million. Shareholders own equity worth $51.69 million.
From a technical analysis perspective, let’s take a brief look at Jounce Therapeutics Inc. (JNCE) price momentum. RSI 9-day as of the close on 29 December was 69.54%, suggesting the stock is Neutral, with historical volatility in this time frame at 197.43%.
As of today, JNCE’s price is $0.9508 +36.90% or $0.3019 from its 5-day moving average. JNCE is currently trading +31.83% higher than its 20-day SMA and -76.76% lower than its 100-day SMA. However, the stock’s current price level is -42.27% below the SMA50 and -84.70% below the SMA200.
The stochastic %K and %D were 71.93% and 64.46%, respectively, and the average true range (ATR) was 0.1794. With the 14-day stochastic at 78.35% and the average true range at 0.1662, the RSI (14) stands at 58.90%. The stock has reached 0.2015 on the 9-day MACD Oscillator while the 14-day reading was at 0.2674.
Robert W. Baird downgraded Jounce Therapeutics Inc. (NASDAQ: JNCE) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Jounce Therapeutics Inc. (JNCE) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JNCE, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.
What is JNCE’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $11.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Jounce Therapeutics Inc. (JNCE) stock is $6.20.